In yesterday’s Wall Street session, Abcam ADR (NASDAQ:ABCM) shares traded at $23.07, down -0.82% from the previous session.
As of this writing, 5 analysts cover Abcam ADR (NASDAQ:ABCM). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $19.81 and a low of $19.02, we find $19.23. Given the previous closing price of $23.26, this indicates a potential downside of -17.33 percent. ABCM stock price is now 0.97% away from the 50-day moving average and 18.97% away from the 200-day moving average. The market capitalization of the company currently stands at $4.75B.
There are 5 analysts who have given it a hold rating, whereas 0 have given it a buy rating. Brokers who have rated the stock have averaged $19.32 as their price target over the next twelve months.
With the price target reduced from $23 to $22, RBC Capital Mkts Downgraded its rating from Outperform to Sector Perform for Abcam ADR (NASDAQ: ABCM).
Thursday morning saw Abcam ADR (NASDAQ: ABCM) opened at $23.20. During the past 12 months, Abcam ADR has had a low of $12.48 and a high of $25.32. As of last week, the company has a debt-to-equity ratio of 0.30, a current ratio of 1.35, and a quick ratio of 1.00. According to the stock market information, the enterprise value for the company is $5.26B, which is based on a 1415.34 price-to-earnings ratio, a 4043.82 price-to-earnings-growth ratio, and a beta of 0.86. The fifty day moving average price for ABCM is $22.85 and a two-hundred day moving average price translates $19.39 for the stock.
The latest earnings results from Abcam ADR (NASDAQ: ABCM) was released for Jun, 2023. The net profit margin was 0.86% and return on equity was 0.44% for ABCM.
Abcam ADR(ABCM) Company Profile
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company’s principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.